rs61752717 — MEFV M694V

The most common and clinically severe MEFV mutation, converting methionine to valine at codon 694 of pyrin; homozygous carriers typically develop full familial Mediterranean fever with early onset, frequent attacks, and high amyloidosis risk if untreated with colchicine

See your personal result for MEFV

Upload your DNA data to find out which genotype you carry and what it means for you.

Upload your DNA data

Works with 23andMe, AncestryDNA, and other DNA test exports. Results in under 60 seconds.

MEFV M694V — The Most Severe Familial Mediterranean Fever Mutation

Familial Mediterranean fever (FMF) is the most common hereditary inflammatory disease in the world, driven by mutations in the MEFV gene that encodes pyrin11 pyrin
also called marenostrin; a multi-domain protein expressed in myeloid cells that acts as a sensor and regulator of the innate immune inflammasome. Of the hundreds of MEFV variants described, M694V stands apart: it is simultaneously the most prevalent pathogenic mutation in the highest-risk populations and the one most consistently linked to severe, treatment-resistant disease. Without colchicine, homozygous M694V carriers face near-certain progression to systemic amyloidosis and renal failure. With it, most can live normal lives — making correct identification the most consequential thing a genetic test can do for this variant.

The Mechanism

MEFV encodes pyrin, a 781-amino acid protein expressed in neutrophils, monocytes, and synovial fibroblasts. Pyrin normally acts as a conditional inflammasome — it assembles an inflammatory signaling complex only when it detects pathogen-derived toxins that inactivate the Rho GTPase pathway. In the resting state, two kinases (PKN1 and PKN2) phosphorylate pyrin at serine residues S208 and S242, keeping the inflammasome inactive by recruiting inhibitory 14-3-3 proteins.

The M694V substitution (methionine → valine at codon 694, in pyrin's B30.2 domain22 B30.2 domain
the C-terminal regulatory domain of pyrin that interacts with viral and bacterial effectors; M694 sits within a loop essential for 14-3-3 binding and PKN1/2 regulation) disrupts this regulatory circuit. Magnotti et al. 201933 Magnotti et al. 2019
Pyrin dephosphorylation is sufficient to trigger inflammasome activation in familial Mediterranean fever patients. EMBO Mol Med, 2019 demonstrated that M694V-expressing monocytes undergo caspase-1-mediated pyroptosis and IL-1β release at concentrations of PKN1/2 inhibitors that have no effect on wild-type cells. The mutation lowers the threshold for pyrin dephosphorylation — so even routine inflammatory stimuli trigger a full inflammasome response that should be reserved for serious pathogen threats. Critically, colchicine completely blocks this response in FMF patient monocytes, explaining its therapeutic efficacy at the molecular level.

The consequence in tissues is recurring, self-limited episodes of serosal and joint inflammation, followed — over years and decades without treatment — by systemic deposition of serum amyloid A (SAA) protein44 serum amyloid A (SAA) protein
AA amyloid, derived from the acute-phase reactant SAA1, deposits in kidneys, liver, spleen, and adrenal glands during chronic inflammation; renal AA amyloidosis is the leading cause of death in untreated FMF.

The Evidence

Genotype-severity correlation. The relationship between M694V and disease severity is one of the most robustly documented in autoimmune genetics. Grossman et al. 201955 Grossman et al. 2019
Familial Mediterranean fever phenotype in patients homozygous to the MEFV M694V mutation. Eur J Med Genet, 2019 compared 94 M694V homozygotes to 134 FMF patients with other genotypes. Severe disease occurred in 89.4% of M694V homozygotes vs. 32.1% of controls (p<0.0001). Before colchicine, M694V homozygotes averaged 23.6 ± 9.3 attacks per year vs. 15.6 ± 11.7 in other genotypes (p=0.0001). Even on treatment, the attack rate remained higher (7.2 vs. 3.5 per year, p=0.0007) and required higher colchicine doses (1.9 vs. 1.48 mg/day, p=0.0001). FMF-related complications — including amyloidosis — occurred in 29.8% of M694V homozygotes vs. 12.5% of controls (p=0.037).

Population enrichment. M694V is the dominant pathogenic MEFV allele across the highest-risk Mediterranean populations. In Turkish FMF patients, M694V accounts for 51.55% of all disease alleles vs. 3% in healthy Turkish controls (overall Turkish carrier rate ~20%; Yilmaz et al. 200166 Yilmaz et al. 2001). Among Armenian-Americans, Ong et al. 201377 Ong et al. 2013 found that 35.3% of double-mutation cases were M694V homozygotes (vs. 2.9% non-Armenians; p=0.0006), and M694V correlated strongly with earlier onset, greater severity, and renal amyloidosis. Carrier rates of 1-in-5 to 1-in-7 in Sephardic Jewish, Turkish, Armenian, and North African Arab populations reflect a founder effect and possible heterozygote advantage (subclinical inflammation may have provided antimicrobial benefit).

Beyond FMF: ankylosing spondylitis. M694V also emerged as a rare major risk variant for ankylosing spondylitis (AS) in a GWAS of Turkish and Iranian cohorts. Li et al. 201988 Li et al. 2019 reported OR=5.3 in Turkish patients, OR=2.9 in Iranians, and OR=5.1 in the combined dataset — the largest-effect rare variant found for AS. In HLA-B27-negative cases, the OR reached 7.8, suggesting that pyrin dysregulation can drive spondylarthropathy through a distinct IL-1-mediated pathway.

Colchicine-resistant disease. When colchicine at maximal dose (up to 3 mg/day) fails to control attacks, IL-1 inhibitors are the evidence-based alternative. Ugurlu et al. 202199 Ugurlu et al. 2021 reported that 45.9% of 98 genotyped FMF patients receiving anakinra were M694V homozygotes, and 75/106 patients achieved complete attack suppression.

Practical Implications

The core management principle is simple but non-negotiable: lifelong colchicine. For M694V homozygotes, this means 1.5–2.0 mg/day (or up to 3 mg/day if attacks persist). The goal is complete suppression of inflammatory episodes because each episode drives SAA production and incremental amyloid deposition. Heterozygous carriers with FMF symptoms also require treatment; asymptomatic heterozygotes need monitoring, as subclinical inflammation may still contribute to amyloid accumulation over decades.

CRP and SAA levels should be checked between attacks — not just during them. Persistently elevated between-attack CRP (>5 mg/L) or SAA signals inadequate inflammasome suppression and warrants dose escalation or IL-1 inhibitor addition. Annual urinalysis (proteinuria screening) detects incipient renal amyloidosis before creatinine rises.

Interactions

M694V homozygosity interacts with the SAA1 gene polymorphism (α allele) — the combination of M694V/M694V genotype and SAA1 α/α significantly elevates amyloidosis risk relative to either factor alone. Male sex is an independent risk factor for amyloidosis development in M694V homozygotes (PMID 12832747).

Compound heterozygotes (M694V on one chromosome + another pathogenic MEFV allele such as M680I, V726A, or E148Q on the other) typically present with intermediate severity — milder than M694V homozygotes but more severe than most single-mutation carriers. The specific compound genotype matters clinically; M694V/M680I tends to produce a phenotype closer to M694V homozygosity than M694V/E148Q.

Drug Interactions

colchicine dose_adjustment literature

Genotype Interpretations

What each possible genotype means for this variant.

TT Non-Carrier Normal

No copies of M694V — no increased FMF risk from this variant

You carry two copies of the reference allele at MEFV M694V and do not carry this specific mutation. You have no increased risk for familial Mediterranean fever from this variant. The M694V allele is rare globally (approximately 0.03% frequency in gnomAD, though substantially higher in Turkish, Armenian, Sephardic Jewish, and Arab populations). The vast majority of the world's population shares your TT genotype at this position.

CT Carrier Carrier

One copy of M694V — heterozygous carrier with possible subclinical inflammation

The inheritance of FMF is classically described as autosomal recessive, but the clinical picture for M694V carriers is more nuanced. Studies have documented subclinical elevation of CRP and SAA between attacks in obligate heterozygotes, and some carriers develop an attenuated FMF phenotype sufficient to warrant colchicine therapy. The key question for any M694V carrier with symptoms is whether a second pathogenic allele exists on the other chromosome — comprehensive MEFV panel sequencing can identify variants that single-site testing misses.

Long-term amyloid risk in asymptomatic heterozygotes is generally low but not zero, particularly in those with persistently elevated inflammatory markers.

CC Homozygous Homozygous

Two copies of M694V — high-severity FMF with significant amyloidosis risk; colchicine required

M694V homozygosity creates a constitutively lowered threshold for pyrin inflammasome activation. Even without frank FMF attacks, subclinical between-attack inflammation (elevated CRP, SAA, fibrinogen) contributes incrementally to amyloid burden over decades. This makes treatment monitoring with between-attack inflammatory markers — not just attack frequency — the appropriate benchmark for therapy adequacy.

When colchicine at maximal dose (up to 3 mg/day) fails to achieve complete attack suppression or normalize between-attack markers, IL-1 inhibitors (anakinra or canakinumab) are the evidence-based second line. In Ugurlu et al. 2021, 45.9% of IL-1 inhibitor recipients were M694V homozygotes, and 75/106 patients achieved complete attack suppression on anakinra.

Associated risks unique to M694V homozygosity include: higher arthritis rates (76.3% vs. 59.1% in other genotypes in amyloidosis cohorts), worse cardiovascular surrogate markers (reduced flow-mediated dilatation, elevated carotid intima-media thickness, higher FGF23 and PTX3 — PMID 35629299), and ankylosing spondylitis risk (OR 5.1–5.3 in Turkish/Iranian cohorts). SAA1 α/α genotype further amplifies amyloidosis risk independently of MEFV genotype.